A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator

NCT00760578 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Placebo
DRUG: Pioglitazone
DRUG: MSDC-0160 90 mg
DRUG: MSDC-0160 220 mg

Sponsor

Metabolic Solutions Development Company